J&J Fends Off Competition for Top Drug, Raises 2017 Forecast

(Bloomberg) -- Johnson & Johnson’s top-selling biotechnology drug Remicade fended off competitors in the third quarter, amid accusations by a rival drugmaker that it’s using unfair tactics to block...

Bloomberg Quint

Add BloombergQuint App to Home screen.